
alexsl
- Baird downgraded Insulet (PODD) to Neutral from Overweight, citing a recent survey that found lower brand loyalty to automated insulin delivery (AID) systems than in the past.
- The firm cut its price target to $158 from $200 (~19% upside based on Friday’s close).
